Summary: Abbott Laboratories is a stable investment in challenging times, with an AA- credit rating
Summary: Thermo Fisher and Abbott are two of our key Healthcare holdings in our fund,
Summary: Abbott Laboratories reported impressive Q3 sales of $10.1B, driven by organic sales growth of
Summary: Wegovy/Ozempic/Mounjaro seem to be driving adoption for ABT’s glucose monitoring equipment, Libre, with 5M
Summary: Abbott Laboratories reported solid growth across all segments in its third-quarter results, excluding its
Summary: Abbott is a well-diversified healthcare company with strong underlying revenue growth and a robust
Summary: Abbott Laboratories is a global healthcare leader known for its branded generic medicines, diagnostic
Summary: Abbott’s adjusted diluted EPS payout ratio is going to expand significantly from the mid-30%
Summary: Abbott Laboratories has experienced a slowdown in growth due to the COVID-19 pandemic ending
Summary: Healthcare investing provides opportunities with wide moats and long-term potential in companies like Abbott